We are live on ! Find out more
ANGO icon

AngioDynamics

157 hedge funds and large institutions have $593M invested in AngioDynamics in 2019 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 63 increasing their positions, 55 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,809% more call options, than puts

Call options by funds: $320K | Put options by funds: $11K

15% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 55

1.76% less ownership

Funds ownership: 100.33%98.57% (-1.8%)

9% less funds holding

Funds holding: 173157 (-16)

14% less capital invested

Capital invested by funds: $692M → $593M (-$98.3M)

41% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 34

Holders
157
Holders Change
-16
Holders Change %
-9.25%
% of All Funds
3.09%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
63
Reduced
55
Closed
34
Calls
$320K
Puts
$11K
Net Calls
+$309K
Net Calls Change
-$94K

ANGO Hedge Fund Activity: Q4 2019 in Review

157 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in AngioDynamics (ANGO) for Q4 2019, worth a combined $593M — down 14% from $692M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of ANGO and 20 opened new positions — a net loss of 14 holders — while 55 trimmed existing stakes and 63 added.

The largest buyer was Victory Capital Management, adding an estimated $8.46M. The largest seller was Lazard Asset Management, exiting entirely with an estimated $28.7M sold.

  • 157 institutional investors held AngioDynamics (ANGO) as of Q4 2019, down from 173 in Q3 2019.
  • Funds reported $593M of AngioDynamics stock for Q4 2019, down 14% quarter-over-quarter.
  • 20 funds opened new AngioDynamics positions in Q4 2019 and 34 closed out, a net change of -14 holders.
  • The largest AngioDynamics buyer in Q4 2019 was Victory Capital Management, an estimated $8.46M added.
  • The largest AngioDynamics seller in Q4 2019 was Lazard Asset Management, an estimated $28.7M sold.

Based on aggregated 13F filings for Q4 2019.